BR9610550A - Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra - Google Patents

Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra

Info

Publication number
BR9610550A
BR9610550A BR9610550A BR9610550A BR9610550A BR 9610550 A BR9610550 A BR 9610550A BR 9610550 A BR9610550 A BR 9610550A BR 9610550 A BR9610550 A BR 9610550A BR 9610550 A BR9610550 A BR 9610550A
Authority
BR
Brazil
Prior art keywords
virus
animal virus
animal
synthetase
activity
Prior art date
Application number
BR9610550A
Other languages
English (en)
Portuguese (pt)
Inventor
Allan S Lau
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of BR9610550A publication Critical patent/BR9610550A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
BR9610550A 1995-08-22 1996-08-22 Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra BR9610550A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US262195P 1995-08-22 1995-08-22
PCT/US1996/013745 WO1997008292A1 (en) 1995-08-22 1996-08-22 Methods for enhancing the production of viral vaccines in cell culture by interferon suppression

Publications (1)

Publication Number Publication Date
BR9610550A true BR9610550A (pt) 1999-07-06

Family

ID=21701659

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610550A BR9610550A (pt) 1995-08-22 1996-08-22 Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra

Country Status (10)

Country Link
US (6) US5840565A (2)
EP (2) EP0846174A4 (2)
JP (2) JP3432519B2 (2)
CN (1) CN1161469C (2)
AT (1) ATE289348T1 (2)
AU (2) AU707130B2 (2)
BR (1) BR9610550A (2)
CA (2) CA2229405C (2)
DE (1) DE69634360T2 (2)
WO (2) WO1997008324A1 (2)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855519B2 (en) * 1995-08-22 2005-02-15 The Regents Of The University Of California Methods for enhancing the production of interferon in cell culture
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US6740519B1 (en) 1997-11-03 2004-05-25 Mount Sinai School Of Medicine Immortalized, homozygous stat1-deficient mammalian cell lines and their uses
KR100637937B1 (ko) * 1998-06-12 2006-10-23 마운트 시나이 스쿨 오브 메디신 오브 뉴욕 유니버시티 변형된 인터페론 길항물질을 보유하고, 백신 및 약제로사용되는 약독화된 네거티브 가닥 바이러스
US6762038B1 (en) 1998-09-09 2004-07-13 The Cleveland Clinic Foundation Mutant cell lines and methods for producing enhanced levels of recombinant proteins
CA2376487A1 (en) * 1999-06-15 2000-12-21 Allan S. Lau Methods for enhancing the production of cytokines in cell culture
EP1067179A1 (en) * 1999-07-09 2001-01-10 Pierre Fabre Medicament Method to select attenuated paramyxoviridae useful for vaccines and therapeutics
AU7126000A (en) * 1999-09-08 2001-04-10 Genetrol Biotherapeutics, Inc. High level cytokine production with enhanced cell viability
US20010031859A1 (en) * 1999-09-08 2001-10-18 Lau Allan S. High level cytokine production with enhanced cell viability
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
IL136232A0 (en) * 2000-05-18 2001-05-20 Bar Ilan University Res Author Measurements of enzymatic activity in a single, individual cell in population
US6660471B2 (en) * 2000-08-04 2003-12-09 Chiron Corporation Enhanced replication of HCV RNA
US20020150541A1 (en) * 2000-09-12 2002-10-17 Gene Trol Biotherapeutics, Inc. Compositions comprising mixtures of therapeutic proteins and methods of producing the same
AU2001290855A1 (en) 2000-09-14 2002-03-26 Genetrol Biotherapeutics, Inc. Method and cell composition for screening compounds for anti-inflammatory activity
US20020115212A1 (en) * 2000-12-19 2002-08-22 Browning Laura A. Enchanced PKR expression and cytokine production
DE10104094C1 (de) * 2001-01-31 2002-07-25 Angelika Vallbracht-Flehmig Verfahren zur Erhöhung der Virusvermehrung und Virusausbeute in Zellkulturen, durch Blockade der RNaseL-Aktivierung
WO2003035824A1 (en) * 2001-10-25 2003-05-01 Bar-Ilan University Interactive transparent individual cells biochip processor
IL154677A0 (en) 2003-02-27 2003-09-17 Univ Bar Ilan A method and apparatus for manipulating an individual cell
EP1654347B1 (en) * 2003-06-26 2014-06-04 Seng Enterprises Limited Improved materials for constructing cell-chips, cell-chip covers, cell-chip coats, processed cell-chips and uses thereof
US8597597B2 (en) 2003-06-26 2013-12-03 Seng Enterprises Ltd. Picoliter well holding device and method of making the same
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7888110B2 (en) 2003-06-26 2011-02-15 Seng Enterprises Ltd. Pico liter well holding device and method of making the same
WO2005008626A1 (en) * 2003-07-11 2005-01-27 University Of North Carolina At Chapel Hill Methods and systems for controlling a computer using a video image and for combining the video image with a computer desktop
US20050064524A1 (en) * 2003-08-11 2005-03-24 Mordechai Deutsch Population of cells utilizable for substance detection and methods and devices using same
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
JP2007529199A (ja) * 2003-10-23 2007-10-25 イルミジェン バイオサイエンシーズ， インコーポレイテッド ウイルス感染に対する抵抗性に関連する遺伝子である、ｏａｓ１における変異の検出
US20050191649A1 (en) * 2003-10-23 2005-09-01 Illumigen Biosciences, Inc. Detection of mutations in a gene associated with resistance to viral infection, OAS1
EP2327724A3 (en) 2004-02-02 2011-07-27 Ambrx, Inc. Modified human growth hormone polypeptides and their uses
BRPI0506610A (pt) * 2004-02-03 2007-05-02 Chemagis Ltd montelucaste sódico amorfo, processo de preparação de montelucaste sódico amorfo, composição farmacêutica, método de tratamento utilizando a administração de montelucaste sódico amorfo, co-precipitado amorfo de montelucaste sódico e processo de preparação de co-precipitado amorfo de montelucaste sódico
NZ548495A (en) * 2004-02-23 2009-05-31 Crucell Holland Bv Virus purification methods
EP3332803B1 (en) 2004-06-01 2021-09-08 Icahn School of Medicine at Mount Sinai Genetically engineered swine influenza virus and uses thereof
EP1763665A1 (en) * 2004-07-07 2007-03-21 Seng Enterprises Limited Method and device for identifying an image of a well in an image of a well-bearing component
US7403647B2 (en) * 2004-09-13 2008-07-22 Seng Enterprises Ltd. Method for identifying an image of a well in an image of a well-bearing component
WO2006021959A2 (en) * 2004-08-25 2006-03-02 Seng Enterprises Ltd. Method and device for isolating cells
US20060051369A1 (en) * 2004-08-27 2006-03-09 Taylor Deborah R ADAR1 antiviral pathway
US20080107683A1 (en) * 2004-11-30 2008-05-08 David Hone Bacterial Packaging Strains Useful for Generation and Production of Recombinant Double-Stranded RNA Nucleocapsids and Uses Thereof
EP1866075B1 (en) 2005-01-25 2010-09-08 Seng Enterprises Limited Microfluidic device for studying cells
WO2006088481A2 (en) 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
UA95446C2 (ru) * 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
DE102005034043B4 (de) * 2005-07-18 2019-12-12 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Gemisch, enthaltend L-Carnitin und Trehalulose, sowie Produkt enthaltend das Gemisch
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
US20070141555A1 (en) * 2005-10-11 2007-06-21 Mordechai Deutsch Current damper for the study of cells
WO2007052245A1 (en) 2005-11-03 2007-05-10 Seng Enterprises Ltd. Method and device for studying floating, living cells
US20070196333A1 (en) * 2006-02-23 2007-08-23 Fu-Yung Lin Composition comprising mixtures of IFN-alpha subtypes
US20060223999A1 (en) * 2006-05-10 2006-10-05 Chemagis Ltd. Process for preparing montelukast and precursors thereof
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
US9145540B1 (en) 2007-11-15 2015-09-29 Seng Enterprises Ltd. Device for the study of living cells
EP2237887A2 (en) 2007-12-26 2010-10-13 Seng Enterprises Ltd. Device for the study of living cells
NZ586947A (en) 2008-02-08 2012-11-30 Ambrx Inc Modified leptin polypeptides and their uses
EP2133358A1 (en) * 2008-06-10 2009-12-16 Universitätsklinikum Freiburg Rift valley fever virus-like particles and their use for immunization and as test system
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines
JP5686741B2 (ja) 2008-12-16 2015-03-18 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ インフルエンザワクチンの生成
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US20140079732A1 (en) 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
WO2013182498A1 (en) * 2012-06-04 2013-12-12 Novartis Ag Improved safety testing
KR20150133695A (ko) * 2013-02-05 2015-11-30 유니버시티 오브 조지아 리서치 파운데이션, 인코포레이티드 바이러스 제조를 위한 세포주 및 이의 사용 방법
JP6722686B2 (ja) 2015-02-26 2020-07-15 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 二価ブタインフルエンザウイルスワクチン
WO2017070167A1 (en) * 2015-10-20 2017-04-27 The University Of North Carolina At Chapel Hill Methods and compositions for modified factor ix fusion proteins
KR102651055B1 (ko) 2016-03-24 2024-03-26 삼성디스플레이 주식회사 광학 필름 및 디스플레이 장치

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33164E (en) * 1979-05-15 1990-02-13 Mobay Corporation Influenza vaccine production in liquid cell culture
JPS5754586A (en) * 1980-09-18 1982-04-01 Ajinomoto Co Inc Cell strain producing human interferon prolongably, its preparation, and preparation of human interferon using it
US4579821A (en) * 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
JPS58209993A (ja) * 1982-05-31 1983-12-07 Mochida Pharmaceut Co Ltd インタ−フエロンの産生方法
CA1211397A (en) * 1982-06-21 1986-09-16 Michael D. Johnston Production of antiviral agents
US4485038A (en) * 1982-10-19 1984-11-27 Health Research (Roswell Park Division) Method for the production and purification of human leukocyte interferon
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4745053A (en) * 1983-07-08 1988-05-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyojo Process for producing human interferon and method for assaying the interferon productivity of blood
JPS6062997A (ja) * 1983-09-17 1985-04-11 Mochida Pharmaceut Co Ltd インタ−フエロンの生産方法
US5196323A (en) * 1985-04-27 1993-03-23 Boehringer Ingelheim International Gmbh Process for preparing and purifying alpha-interferon
US4732683A (en) * 1986-12-02 1988-03-22 Biospectrum, Inc. Purification method for alpha interferon
EP0414475B1 (en) * 1989-08-25 1997-12-10 Chiron Corporation Methods for culturing HCV in B- or T-lymphocyte cell lines
US5149531A (en) * 1990-06-27 1992-09-22 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using cold-adapted live influenza virus vaccine as an antiviral agent against influenza
JPH05260981A (ja) * 1992-03-02 1993-10-12 Massachusetts Inst Of Technol <Mit> ヘムに調節される真核細胞開始因子２αキナーゼをコードするＤＮＡ
FR2689520B1 (fr) * 1992-04-03 1996-07-19 Bio Merieux Procede et milieu de culture pour l'obtention de cellules infectees par un virus associe a la sclerose en plaques.
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture

Also Published As

Publication number Publication date
EP0846160B1 (en) 2005-02-16
AU6860896A (en) 1997-03-19
JP4267693B2 (ja) 2009-05-27
US6489144B1 (en) 2002-12-03
JP3432519B2 (ja) 2003-08-04
AU6857696A (en) 1997-03-19
US6686190B2 (en) 2004-02-03
CA2229163A1 (en) 1997-03-06
CN1200148A (zh) 1998-11-25
US20040157310A1 (en) 2004-08-12
US20010001709A1 (en) 2001-05-24
US20010001290A1 (en) 2001-05-17
AU707130B2 (en) 1999-07-01
EP0846160A1 (en) 1998-06-10
JPH11511324A (ja) 1999-10-05
ATE289348T1 (de) 2005-03-15
EP0846160A4 (en) 2002-01-02
US5840565A (en) 1998-11-24
CN1161469C (zh) 2004-08-11
EP0846174A4 (en) 2003-02-05
EP0846174A1 (en) 1998-06-10
US7132271B2 (en) 2006-11-07
WO1997008292A1 (en) 1997-03-06
CA2229405A1 (en) 1997-03-06
DE69634360T2 (de) 2005-12-29
US6159712A (en) 2000-12-12
JPH11514344A (ja) 1999-12-07
DE69634360D1 (de) 2005-03-24
US6673591B2 (en) 2004-01-06
CA2229163C (en) 2011-04-05
CA2229405C (en) 2004-03-02
WO1997008324A1 (en) 1997-03-06
MX9801423A (es) 1998-05-31

Similar Documents

Publication Publication Date Title
BR9610550A (pt) Método para a produção de uma vacina viral para um vírus animal método para determinar a atividade de um composto contra um vírus animal e método para detectar a presença de um vírus em uma amostra
BR0212470A (pt) Métodos para produção de um ingrediente ativo de uma droga ou agente diagnóstico em cultura em suspensão de células mdck
SI1427817T1 (sl) Razmnoževanje virusov in celičnih kultur
Daniel et al. Bacteriophage Induced Transfer RNA in Escherichia coli: New transfer RNA molecules are synthesized on the bacteriophage genome.
Handa et al. Transcription of Simian virus 40 DNA in a HeLa whole cell extract.
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
BRPI0407636A (pt) meio de cultura de células, linhagem de células animais, métodos para produzir um meio de cultura condicionado, células animais, uma cultura de células animais, vìrus em uma cultura de células animais, ou, de preferência, humanas diplóides dependentes de ancoragem, método para produzir uma vacina, e, população de vìrus
Sibler et al. Codon reading patterns in Saccharomyces cerevisiae mitochondria based on sequences of mitochondrial tRNAs
Friesen et al. Black beetle virus: messenger for protein B is a subgenomic viral RNA
HUP0402415A2 (hu) Eljárás vírusantigén nagy méretekben történő termelésére
UA48936C2 (uk) Спосіб одержання вірусу курячої анемії (cav) у дволанцюговій формі, рекомбінантна нуклеїнова кислота (варіанти), діагностичний набір (варіанти), вакцинний препарат (варіанти), культура клітин (варіанти), спосіб одержання діагностичного набору (варіанти)
Cash et al. Genome complexities of the three mRNA species of snowshoe hare bunyavirus and in vitro translation of S mRNA to viral N polypeptide
HOVANESSIAN Intracellular events in interferon-treated cells
DK0458901T3 (da) Hæmning af transformation af celler med forhøjet purin-metabolisk enzymaktivitet
Miyamoto et al. Mechanism of interferon action Interferon-mediated inhibition of reovirus mRNA translation in the absence of dettectable mRNA degradation but in the presence of protein phosphorylation
Thiebe et al. Acceptor activity in homologous and heterologous combinations of half molecules from tRNAyeastPhe and tRNAwheatPhe
Weeks et al. Transcribing and replicating particles in a double-stranded RNA virus from Leishmania
ATE366803T1 (de) Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit
Coppola et al. Discriminatory inhibition of protein synthesis in cell-free systems by vaccinia virus transcripts.
DE60130465D1 (de) Mutierte muskelspezifische enhancer
Fallon Isolation of ribosomal subunits from cultured mosquito cells
Alhonen-Hongisto et al. Tumourigenicity, cell-surface glycoprotein changes and ornithine decarboxylase gene pattern in Ehrlich ascites-carcinoma cells
EP1562635A4 (en) MODIFIED DENDRITIC CELLS
Sawabe et al. Genetic differentiation among three populations of Anopheles minimus of Guangxi and Yunnan Provinces in the People's Republic of China
Patch et al. Regulation of viral transcription in cells infected with iododeoxyuridine-substituted simian virus 40 as a model for the activation by iododeoxyuridine of latent viral genomes

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE COMO INVENCAO, DE ACORDO COM ARTIGO 8O DA LPI